Oncopeptides AB (publ) (0RN4.L)

35.44 -0.77 (-2.12%) As of 05:21PM BST. Market open.

Oncopeptides AB (publ)

Vastra Tradgardsgatan 15
Stockholm 111 53
Sweden
46 86 15 20 40
https://www.oncopeptides.com/sv

Sector(s): 
Industry: 
Full-time employees: 57

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Jakob Lindberg Med. Lic	Chief Scientific Officer	7.26M	N/A	1972
Ms. Sofia Heigis M.Sc.	Chief Executive Officer	N/A	N/A	1980
Prof. Rolf Larsson M.D., Ph.D.	Founder	N/A	N/A	N/A
Prof. Rolf Lewensohn M.D., Ph.D.	Founder	N/A	N/A	N/A
Dr. Joachim Gullbo M.D., MSc Pharm, Ph.D.	Founder	N/A	N/A	N/A
Dr. Kristina Luthman Ph.D.	Founder	N/A	N/A	N/A
Prof. Hans Ehrsson M.D.	Founder	N/A	N/A	N/A
Mr. Peter Nygren	Founder	N/A	N/A	1959
Mr. Henrik Bergentoft	Chief Financial Officer	N/A	N/A	1974
Ms. Eva Nordström M.Sc., MSc Pharm	COO & Deputy MD	N/A	N/A	1970

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Oncopeptides AB (publ), a biotech company, engages in the commercialization, and research and development of treatments for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is melflufen, a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden

Corporate governance

Oncopeptides AB (publ)’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.